Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like the company board members are selling shares still, probably tax write off sells...
Oh wait, their shares were free, they get no tax write off!!!
LMAO, BASTARDS. And a Merry Christmas to we bag holders.
Certainly an element of risk and some retail selling as well, but there is something to be said about the reward if this bounces back on better news in the future. High risk high reward… even more so at this point.
India AND Pakistan. I'm not sure the dilution should've taken it down this far - alone. I wonder if there's something to the FDA bring stringent - though they are mitigating. OR... I wonder if now is the time to invest. No lack of risk here...
Thanks. Pretty strange as you stated on why second trial has not been authorized yet. In the meantime, looks like dilution. Hopefully they are done for now.
They use ivermectin and hcq there! No need for anything else
They had a release. It states Pakistan / India - they've had no response to continue their studies. SEC investigation... still ongoing. And Potential issue from how the FDA perceives their work... however, they do not expect impacts and have mitigations.
I wonder why the Pakistan and India "trials" haven't moved forward. The results were good, it seems.
Ugly day. I would assume dilution to raise capital...or worst yet, insider dumping.
Major drop today... anyone have a chance to dissect why?
Looks like PPS is bouncing from lows
The board members gifted themselves tons of shares, Covid was like hitting the lottery for them.
Let's see how low they crash the stock, maybe a good flip opportunity will come first of the new year.
I haven't seen any news for awhile... dropping down into interesting territory right now. By Interesting... it could be bad interesting as well. The stock was diluted and will drop below .05... but without any (good) news...
The people in management are destroying this stock, they gave themselves tons of shares and turn around and sell them at a nickel. Basically milking everything they can from the stock.
I unloaded quite a few shares at 12 pennies, no regrets at this point
Wow, someone's getting desperate to be flashing over 3mm shares for sale with new mm vert on the bid and vndm (notorious short) on the offer.
Tic toc
Someones buying heavily and someone's selling heavily. Is it real selling or shorts pressing their luck?? By the names of MMs making a market here it "appears" to be shorts caught and doing everything they can to hold the price down??? If it is a short and by the looks of it there's a real battle going on at these levels.. the price will break hard in one direction or the other very soon imo. Which way will she break out to???tic toc
New tweet!: We’re pleased to share we have received Orphan Drug Designation from the European Medicines Agency, for QIXLEEF™, as a potential treatment for Complex Regional Pain Syndrome, a chronic neuropathic pain condition. $TBP $TBPMF
We’re pleased to share we have received Orphan Drug Designation from the European Medicines Agency, for QIXLEEF™, as a potential treatment for Complex Regional Pain Syndrome, a chronic neuropathic pain condition. $TBP $TBPMF pic.twitter.com/04vTyDGW3A
— Tetra Bio-Pharma (@TetraBioPharma) November 16, 2021
I'm surprised there isn't that much excitement about the OTCQB news which will attract institutional investors. This is a big deal!
SO, AVERAGE NOW IS ZERO. that's gonna affect the gains tax
Miami, FL (November 9, 2021) — Organicell Regenerative Medicine, Inc. (OTCQB: OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that its application to uplist its common stock to the OTCQB Venture Market (the “OTCQB”) has been approved by OTC Markets Group, Inc. Organicell’s common stock will commence trading on the OTCQB under the symbol “OCEL” commencing at the opening of the market on November 9, 2021.
The OTCQB, operated by OTC Markets Group Inc., is designed for developing and entrepreneurial companies in the United States and abroad. To be listed on OTCQB, companies must be current in their financial reporting and undergo an annual verification and management certification process, including meeting a minimum bid price and other financial conditions. With more compliance and quality standards, the OTCQB provides investors improved visibility to enhance trading decisions. The OTCQB is recognized by the United States Securities and Exchange Commission as an established public market providing public information for analysis and value of securities and trading.
Albert Mitrani, CEO, commented, “our listing on the OTCQB is another important milestone for Organicell. It will provide us greater visibility within the investment community, which should increase our access to institutional and retail investors. This additional capital markets exposure will be valuable, as we expect to pursue capital raising opportunities to support our planned clinical trials in connection with the Company’s lead product, Zofin™”.
About Zofin™
Zofin™ is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin™ contains over 300 growth factors, cytokines, and chemokines as well as extracellular vesicles/nanoparticles.
ABOUT ORGANICELL REGENERATIVE MEDICINE, INC.
Organicell Regenerative Medicine, Inc. (OTCQB: OCEL) is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit https://organicell.com/.
FORWARD-LOOKING STATEMENTS
Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as “will”, “believes”, “expects”, “potential”, or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company’s periodic reports that are filed with the SEC and available on the SEC’s website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.
Media Contact:
Joshua Rodriguez
Joshua@CNAFinance.com
(503) 464-6502
Huge news! Uplifting to OTCQB
Organicell announces its application to uplift its common stock to the OTCQB Venture Market (the “OTCQB”) has been approved by OTC Market Group, Inc. Effective November 9, 2021, common stock will commence trading on the OTCQB under the symbol $OCEL.
— Organicell (@organicellTM) November 9, 2021
https://t.co/Z285ewzTUm pic.twitter.com/crYNOuRBue
Oh wow, how’s it going? I wish you well!
the mcd I work at now has 59nemployees on schedule. 2 shifts, thats not just this store, thats the way it is with all of them. assembly line, they just brought back one of their models, the famous McRib,
i'm still waiting for results of the India trials
I'm in one of those trials
Effective Nov. 8,2021 BPSR will change to OCEL:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
Trying to figure out the new floor with the 250m shares in dilution. At least that appears to be the news. Any other takes on it?
Cheers. I think the Reward vs. Risk is worth it. GL to us Lol
Great looking chart. Just added a bunch myself. Thanks.
one of the conditions for an Emergency Use Authorization (EUA) is there must be no approved therapeutic available for the disease https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
there are two windows . The first is from .06 through .34 check the daily chart..possible bull trap here
PPS is going back up!
We are almost down to .05... I wonder If this is not going to stop this time... and if the Merck news is a bpsr killer.
I haven’t seen anything specific, however the CEO did mention raising capital through the market which to me spells short term dilution. This is common for pharmaceutical start ups.
Does anyone think there is still room for Organicell with Merck's Covid pill?
Are you able to provide specific wording?
I received a thing from trader ameri that’s what it looked like
I saw your tweet to Organicell.
Have you heard anything going on right now? I see nothing on clinicaltrials or any other site. I Do not see where they were diluting (per one of the other comments above).
Curious if you saw or heard anything.
Anyone know what’s up with the recent larger drop?
Where do you see that? Maybe I missed it.. but reading through the recent releases, I do not see where they issued more stock or put more on the market.
Sure would like to know how things are going in Pakistan
This company needs to update people seriously. I am waiting
Followers
|
76
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1990
|
Created
|
07/10/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |